CFTR and cystic fibrosis: For instance, the cystic fibrosis drug Trikafta [16], which combines two correctors to promote proper folding and trafficking of the F508del CFTR mutant and a potentiator to enhance channel activity, has significantly improved outcomes in patients with folding-defective variants.